• Langley Road, Brighton, MA
  • 416-402-8274

NIH Licensing Opportunity: Breakthrough Science to Treat Colon Cancer and Glioblastoma


  • Register



This webinar already occurred on Apr 1, 2020 but a recording can be watched below:

Signature Square OMSIH logo

Treating Cancers (e.g., Glioblastoma and Colon Cancer) Using a Unique, Repurposed Peptide Inhibitor of CDK5/p25 Complex Activity

One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square™ process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.

Treating Cancers (e.g., Glioblastoma and Colon Cancer) 

This webinar will introduce a modified peptide inhibitor of CDK5/p25 complex activity that can treat cancers (e.g., glioblastoma and colon cancer) causing abnormal regulation of central nervous system (cns) processes. This technology has demonstrated dramatic increases in survival in mouse models and qualifies for FDA Fast Track and Orphan Drug Status in Glioblastoma.

GBM is the most aggressive form of brain cancer. The current standard of care against GBM is a combination of surgery, chemotherapy and radiotherapy. However, after standard treatment, the cancer usually recurs – emphasizing a need for new targets and better alternatives. A promising target is cyclin-dependent kinase 5 (CDK5), the hyperactivity of which has been shown to have a role in cancer progression. 

TP5/TFP5, a small peptide inhibitor against CDK5, was developed at the National Institutes of Health and modified to increase its passage through the blood brain barrier. Researchers at the NCI and NINDS demonstrated that TP5 decreases cell viability and increases programmed cell death in GBM and CRC cell lines with aberrant CDK5 activity. TP5 was found to impair DNA repair by inhibiting CDK5 and acted additively and synergistically with DNA-damaging agents (e.g. temozolomide, irinotecan, irradiation) used in treatment of GBM and colon carcinoma. TP5 decreased the tumor volume and increased the overall survival of orthotopic glioblastoma mouse models.

This is an opportunity to LICENSE THIS TECHNOLOGY, or participate in further collaborative work to enhance its development.

The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.

This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.

Zhengping Zhuang, M.D., Ph.D.
Neuro-Oncology Branch
Center for Cancer Research
National Cancer Institute
Herui Wang, Ph.D.
Postdoctoral Researcher
Center for Cancer Research
National Cancer Institute
Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™